コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 able muscle weakness resulting from impaired neuromuscular transmission.
2 athological conditions with reduced synaptic neuromuscular transmission.
3 receptor (AChR) on muscle and interfere with neuromuscular transmission.
4 rget the ion channels that are essential for neuromuscular transmission.
5 eterogeneous group of inherited disorders of neuromuscular transmission.
6 e of MEPCs, preserving the safety factor for neuromuscular transmission.
7 d/or to concomitant use of drugs that affect neuromuscular transmission.
8 g presynaptic cytosolic [Ca2+] during normal neuromuscular transmission.
9 acilitate action potential generation during neuromuscular transmission.
10 to delay or reverse BoNT-induced blockade of neuromuscular transmission.
11 udies, and has advanced our understanding of neuromuscular transmission.
12 nce of slow AChR ion channels, and defective neuromuscular transmission.
13 up of rare genetic disorders that compromise neuromuscular transmission.
14 likely to be crucial for ensuring effective neuromuscular transmission.
15 rtance of glycosylation for the integrity of neuromuscular transmission.
16 e group of heterogeneous disorders affecting neuromuscular transmission.
17 sorders that compromise the safety margin of neuromuscular transmission.
18 loroquine may worsen or provoke disorders of neuromuscular transmission.
19 r se is not a reliable indicator of impaired neuromuscular transmission.
20 me (LEMS) are autoimmune disorders affecting neuromuscular transmission.
21 esponse, thus reducing the safety margin for neuromuscular transmission.
22 ptic facilitation, and attenuated inhibitory neuromuscular transmission.
23 stsynaptic membrane and may lead to enhanced neuromuscular transmission.
24 oup of rare diseases resulting from impaired neuromuscular transmission.
25 ding proteins essential for the integrity of neuromuscular transmission.
26 otransmitter release, which leads to minimal neuromuscular transmission.
27 e action potentials (CMAPs), and compromised neuromuscular transmission.
28 g frog, use the P/Q-type calcium channel for neuromuscular transmission.
29 tested had results consistent with abnormal neuromuscular transmission.
30 ymptoms, including reduced CMAP and impaired neuromuscular transmission.
31 n pathway and that manifest through impaired neuromuscular transmission.
32 lly induced blockade of action potentials or neuromuscular transmission.
33 importantly to the reduced safety margin of neuromuscular transmission.
34 ispersed synaptic AChR clusters and impaired neuromuscular transmission.
35 astatin (CS) transgene improved strength and neuromuscular transmission.
36 y SFEMG, confirming the presence of impaired neuromuscular transmission.
37 c currents in the unc-9 mutant showed normal neuromuscular transmission.
38 m any abnormality in the immediate events of neuromuscular transmission.
39 ndicate that the defect is not manifested in neuromuscular transmission.
40 lpha(2)betadelta(2) pentamers cannot sustain neuromuscular transmission.
41 elease of acetylcholine and eventually block neuromuscular transmission.
42 hallmark of LEMS is a large potentiation of neuromuscular transmission after high-frequency stimulat
43 NA could generate sufficient AChR to support neuromuscular transmission, albeit at a reduced level.
44 gravis (MG), anti-AChR autoantibodies impair neuromuscular transmission and cause severe muscle weakn
45 knock-in mouse model of EA1 and restored the neuromuscular transmission and climbing ability in Shake
46 age at subsynaptic nuclei, and improved both neuromuscular transmission and clinical measures of moto
47 on excitability produced by manipulations of neuromuscular transmission and compared these with the e
48 , but significant changes in NMJ morphology, neuromuscular transmission and EMG data were found only
49 verified that these evoked twitches involved neuromuscular transmission and faithfully reported muscl
50 emonstrate improved muscle fatigue, improved neuromuscular transmission and improved synaptic structu
51 nn cells are discussed as avenues to improve neuromuscular transmission and maintain muscle strength.
53 nel that plays important roles in regulating neuromuscular transmission and muscle fiber excitability
54 cetylcholine receptor, reduced efficiency of neuromuscular transmission and muscle weakness and fatig
55 potentials were reduced, indicating impaired neuromuscular transmission and providing cellular mechan
56 sies for in vitro microelectrode analysis of neuromuscular transmission and quantitative electron mic
57 d our understanding of genes associated with neuromuscular transmission and resistance to the antinem
58 at sit atop the neuromuscular junction sense neuromuscular transmission and respond to perturbations
59 study, we examined the relationship between neuromuscular transmission and skeletal muscle hyperexci
61 oss brain development, muscle contractility, neuromuscular transmission, and lung development were ru
63 opment of the NMJ, homeostatic regulation of neuromuscular transmission, and synaptic gene expression
64 remodelling is associated with impairment of neuromuscular transmission, and that this contributes to
65 annel mediates fast inhibitory glutamatergic neuromuscular transmission; and (ii) a nematocidal prope
67 congenital myasthenic syndromes or impaired neuromuscular transmission as part of a more severe mult
68 n synaptic gene expression, development, and neuromuscular transmission, as well as mediating degener
69 both presynaptic and postsynaptic aspects of neuromuscular transmission at concentrations close to th
70 It is suggested that this is due to weak neuromuscular transmission at synapses in the process of
71 nd function of individual NMJs, we show that neuromuscular transmission at the most highly fragmented
72 re reviewed: a) the developmental changes in neuromuscular transmission; b) the pharmacokinetics and
73 we use paired patch clamp recording to study neuromuscular transmission between the caudal primary mo
74 dTC, which rescues motoneurons and blocks neuromuscular transmission, blocked neither spontaneous
76 dy, we investigate effects of these drugs on neuromuscular transmission by conventional microelectrod
77 ynaptic actions of K+ channels in Drosophila neuromuscular transmission by using electrophysiological
78 igable muscle weakness results from impaired neuromuscular transmission caused by reduced AChR number
79 nherited disorders that result from impaired neuromuscular transmission, caused by mutations in genes
80 that in zebrafish twister mutants, prolonged neuromuscular transmission causes motor axonal extension
81 SCCMS) is a dominantly inherited disorder of neuromuscular transmission characterized by delayed clos
82 (CMSs) are a group of inherited disorders of neuromuscular transmission characterized by fatigable mu
83 sthenic syndromes are inherited disorders of neuromuscular transmission characterized by fatigable mu
84 rogeneous collection of genetic disorders of neuromuscular transmission characterized by fatiguable m
86 muscle degeneration and dystrophy, impaired neuromuscular transmission contributes to muscle weaknes
87 otility indicating that decreased purinergic neuromuscular transmission could contribute to the infla
91 patients with apparent distal myopathy for a neuromuscular transmission disorder and agrin mutations.
94 ectable autoantibodies and confirmation of a neuromuscular transmission disorder relies on specialize
95 tial for sustaining phasic release, and thus neuromuscular transmission, during and following tetanic
99 ve evidence of any significant impairment in neuromuscular transmission, even when animals were maint
104 tibody positive myasthenia gravis results in neuromuscular transmission failure since MuSK antibodies
105 nd AChR function as well as those that cause neuromuscular transmission failure upon Ab binding.
107 TrkB kinase activity had similar effects on neuromuscular transmission failure, supporting a critica
108 ysiological methods revealed that functional neuromuscular transmission first occurs quite early duri
109 of the CSP gene causes impaired presynaptic neuromuscular transmission in Drosophila melanogaster, i
110 confers a marked temperature-sensitivity to neuromuscular transmission in postnatal day 14 (P14)-P21
112 This study was undertaken to investigate neuromuscular transmission in regions of the inflamed co
117 We conclude that the temperature-sensitive neuromuscular transmission is accounted for solely by a
123 the normal situation, the safety factor for neuromuscular transmission is ensured by the large INa a
125 hich muscle weakness resulting from impaired neuromuscular transmission is often present from infancy
127 ectrum of clinical features where deficit in neuromuscular transmission is the major component in a s
128 henia gravis (MG), an autoimmune disorder of neuromuscular transmission, is treated by an array of im
129 otrophic lateral sclerosis (ALS) that blocks neuromuscular transmission, leading to muscle weakness,
131 s contributes to the reduction in purinergic neuromuscular transmission measured in animal models of
132 polypeptide (VIP) participates in inhibitory neuromuscular transmission (NMT) in the internal anal sp
133 neurophysiological studies suggest abnormal neuromuscular transmission occurs in some cases of Mille
134 mutating gap junction proteins and blocking neuromuscular transmission on the synchrony of action po
136 slow MyHC gene expression did not occur when neuromuscular transmission or depolarization was blocked
137 a clinical hallmark of LES, facilitation of neuromuscular transmission produced by vigorous voluntar
139 affected MG rats, ClC-1 inhibition enhanced neuromuscular transmission, restored muscle function, an
140 in guinea pig, leads to decreased purinergic neuromuscular transmission resulting in a reduction in i
141 is caused by a potent neurotoxin that blocks neuromuscular transmission, resulting in death by asphyx
142 agnostic studies evaluating for disorders of neuromuscular transmission should focus on proximal limb
144 gravis (MG) is a well-recognised disorder of neuromuscular transmission that can be diagnosed by the
145 tion of this effect to the safety factor for neuromuscular transmission, the ratio of the normal quan
146 acetylcholine receptors (AChRs) that impair neuromuscular transmission, thereby causing muscle weakn
147 bination with 3,4-DAP significantly restored neuromuscular transmission to control levels in both a m
148 ity of roscovitine, known to potentiate frog neuromuscular transmission, to mediate behavioral and fu
154 further insight into how these drugs affect neuromuscular transmission, we investigated their effect
155 r, although deficits in nerve conduction and neuromuscular transmission were observed in myd animals,
156 autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the bindi
157 ividual as progressive weakness and impaired neuromuscular transmission without overt degeneration of